MGI:96787Homozygotes for targeted null mutations have reduced numbers of stem cells in spleen and bone marrow, enhanced inflammatory responses, impaired sensory neuron regrowth, and uterine insufficiency. Heterozygotes show intermediate numbers of stem cells.